Wei Zhang

Prof. Wei Zhang

The First Affiliated Hospital of Chongqing Medical University

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
DPDong Peng
Dong Peng
YCYu-Xi Cheng
Yu-Xi Cheng
WZWei Zhang
Wei Zhang
Introduction To evaluate whether the extent of gastrectomy or the reconstruction method brings benefit of type 2 diabetes mellitus (T2DM) remission after gastrectomy in patients with gastric cancer. Methods PUBMED, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library were searched to find eligible studies published from inception to July 31, 2020. Results A total of nine studies (1424 patients) were included. At the first year and the end of follow-up time after gastrectomy, the total gastrectomy group had better T2DM remission than the subtotal gastrectomy group, and the Roux-en-Y reconstruction (R-Y) group had better T2DM remission compared with the non-R-Y group. There was no difference between R-Y and non-R-Y in terms of subtotal gastrectomy (OR 1.08, 95% CI 0.63–1.84, P = 0.78). However, total gastrectomy with R-Y had better T2DM remission than subtotal gastrectomy with R-Y (OR 2.75, 95% CI 1.19–6.35, P = 0.02). Conclusion Total gastrectomy with R-Y had better T2DM remission. The extent of gastrectomy rather than the reconstruction method might play an important role in T2DM remission after gastrectomy in patients with gastric cancer.

1 August 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
DPDong Peng
Dong Peng
YCYu-Xi Cheng
Yu-Xi Cheng
WTWei Tao
Wei Tao
YZYing-Ying Zou
Ying-Ying Zou
KQKun Qian
Kun Qian
WZWei Zhang
Wei Zhang
Purpose: The purpose of this study was to explore the changes in blood pressure in patients with concurrent gastric cancer and hypertension after gastrectomy, and to identify the factors that affect the changes in blood pressure. Materials and Methods: Patients with concurrent gastric cancer and hypertension who underwent gastrectomy were retrospectively analyzed from January 2013 to December 2018. The pre- and 6-month postoperative medical records were compared. Predictors for the remission of hypertension were analyzed. Results: A total of 143 patients with concurrent gastric cancer and hypertension were included in this study. The number of patients with complete remission, partial remission and no remission were 67 (46.9%), 12 (8.4%) and 64 (44.7%), respectively. The average of weight and BMI (body mass index) before gastrectomy were 63.0 ± 9.7 kg and 23.4 ± 2.9 kg/m2, respectively, which were significantly higher than those 6-month postgastrectomy: 54.8 ± 9.8 kg and 20.4 ± 3.1 kg/m2, respectively (p< 0.001). The average number of antihypertensive medications before gastrectomy was 1.5 ± 0.6, while it was 0.8 ± 0.8 6-month postgastrectomy (p< 0.001). Age (p< 0.05) and the surgical techniques used (p< 0.05) were significantly different between partial remission and no remission patients. Furthermore, age (p< 0.05) and the surgical techniques used (p< 0.05) were significantly different between complete remission and no remission patients. Age (p< 0.05, odds ratio =0.933, 95% CI=0.890– 0.978) and the surgical techniques used (p< 0.05, odds ratio =2.749, 95% CI=1.132– 6.677) are predictors for remission of hypertension. Conclusion: Total gastrectomy is an onco-metabolic surgery that can cure younger patients with concurrent gastric cancer and hypertension. Age and the surgical techniques used can predict the remission of hypertension 6 months after gastrectomy.

1 March 2021 in Risk Management and Healthcare Policy
Verified
Journal Article
Open access
PDF file
DPDong Peng
Dong Peng
YZYing-Ying Zou
Ying-Ying Zou
YCYu-Xi Cheng
Yu-Xi Cheng
WTWei Tao
Wei Tao
WZWei Zhang
Wei Zhang
Purpose: The purpose of the present study was to evaluate the effect of time (season, surgical starting time in the daytime, preoperative waiting time) on patients with gastric cancer. Methods: A retrospective collection of medical records of patients who underwent gastrectomy at a single clinical center from January 2013 to December 2018 was performed. Medical records were collected, and short-term outcomes and long-term survival were analyzed by different time groups. Results: A total of 586 patients were included in this study. In terms of surgical starting time, the midday group had a shorter operation time (p=0.017) but more complications (p=0.048) than the non-midday group. No significant difference was found based on the season of gastrectomy. The long preoperative waiting group had a shorter postoperative hospital stay than the short waiting group (p=0.026). No significant difference was found between the short-waiting group and long-waiting group in overall survival for all clinical stages. Age (p=0.040, HR=1.017, 95% CI=1.001– 1.033), BMI (p< 0.001, HR=0.879, 95% CI=0.844– 0.953) and clinical stage (p< 0.001, HR=2.053, 95% CI=1.619– 2.603) were independent prognostic factors predicting overall survival; however, season of gastrectomy, surgical starting time and preoperative waiting time were not identified as independent prognostic factors. Conclusion: Surgical starting time at the midday could cause more complications, and surgeons should be careful when the surgical starting time is midday.

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
DFDapeng Feng
Dapeng Feng
ZLZhengwei Li
Zhengwei Li
LYLiang Yang
Liang Yang
HLHaidong Liang
Haidong Liang
HHHongtao He
Hongtao He
WZWei Zhang
Wei Zhang
Bone marrow mesenchymal stem cells (BMSCs) can boost osteosarcoma (OS) cell proliferation and invasion, yet the function of extracellular vesicles (EVs) derived from BMSCs on OS is scarcely known. This study is aimed at examining the role of BMSC‐EVs in OS cells. BMSCs and BMSC‐EVs were isolated and identified. The effect of EVs and EVs‐si‐NORAD on OS cell proliferation, invasion, migration, and angiogenesis was determined. Expressions of NORAD, miR‐877‐3p, and CREBBP were detected. The binding relationship among NORAD, miR‐877‐3p, and CREBBP was verified. The miR‐877‐3p inhibitor or pc‐CREBBP was delivered into OS cells treated with EVs‐si‐NORAD for in vitro analysis. The nude mouse model of the subcutaneous tumor xenograft was established for in vivo analysis. BMSC‐EVs promoted OS cell proliferation, invasion, migration, and angiogenesis. BMSC‐EVs carried NORAD into OS cells and upregulated CREBBP by sponging miR‐877‐3p. miR‐877‐3p downregulation or CREBBP overexpression partly inverted the inhibitory effect of EVs by silencing NORAD on OS cell proliferation, invasion, migration, and angiogenesis. In vivo experiments validated that BMSC‐EV‐derived NORAD facilitated tumor growth by upregulating CREBBP via miR‐877‐3p. To conclude, BMSC‐EV‐derived NORAD facilitated OS cell proliferation, invasion, migration, and angiogenesis by modulating CREBBP via miR‐877‐3p, which may offer new insights into OS treatment.

25 March 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
HHHongtao He
Hongtao He
MDMuliang Ding
Muliang Ding
TLTao Li
Tao Li
WZWenzhi Zhao
Wenzhi Zhao
LZLu Zhang
Lu Zhang
WZWei Zhang
Wei Zhang

1 January 2014
Verified
Journal Article
Open access
XGXiaoling Guan
Xiaoling Guan
HYHuajie Yang
Huajie Yang
WZWei Zhang
Wei Zhang
HWHuanjun Wang
Huanjun Wang
LLLin Liao
Lin Liao
To review the advances of studies on vitamin D receptor and its role in the pathogenesis of diabetic nephropathy. A comprehensive search of the PubMed literatures without restriction on the publication date was carried out using keywords such as vitamin D receptor and diabetic nephropathy. Articles related to vitamin D receptor and diabetic nephropathy were selected and carefully analyzed. The ligands as well as construction and tissue distribution of vitamin D receptor were summarized. Pathogenesis of diabetic nephropathy was analyzed. The mechanisms underlying the renoprotective role of vitamin D receptor including inhibition of renin-angiotensin system, anti-inflammation, anti-fibrosis and the reduction of proteinuria were reviewed. Mounting evidences from animal and clinical studies have suggested that vitamin D therapy has beneficial effects on the renal systems and the underlying renoprotective mechanisms of the vitamin D receptor-mediated signaling pathways is a hot research topic. Our study suggests that vitamin D receptor has a great potential for preventing the progression of diabetic nephropathy via multiple mechanisms.